Skip to content

Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections

Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00774098
Enrollment
60
Registered
2008-10-17
Start date
2007-01-31
Completion date
2009-09-30
Last updated
2010-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Function

Keywords

all adult patients (>18 years) planned to undergo a major liver resection

Brief summary

We would like to study the effect of preserving liver glycogen storage by using intravenous dextrose infusion on postoperative liver function and complications after major liver resections.

Interventions

DRUGdextrose 10% (D10W ®) infusion

Started at 8pm the day before surgery until the procedure begins

Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively

DIETARY_SUPPLEMENThigh calorie diet 35 kcal/kg

High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery

Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * planned to undergo a major liver resection at McGill University Health Center (MUHC)

Exclusion criteria

* patients known with chronic viral liver disease * uncontrolled or type one diabetes mellitus (DM) * patients on oral beta-blocker agents * patients with unresectable disease determined intra-operatively * patients unable to give consent for the study.

Design outcomes

Primary

MeasureTime frame
Postoperative liver function testPostoperative

Secondary

MeasureTime frame
Liver and muscle glycogen, TG, and protein content at beginning and end of the procedure.Begining + end of the procedure
Incidence of complicationsPostoperative

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026